CD137 (4-1BB) is a promising target for cancer immunotherapy. Its ability to stimulate T cells and enhance tumor cell killing has drawn attention from researchers and pharmaceutical companies.

Despite the absence of approved CD137-targeted therapies, numerous candidates are under clinical development. Major companies like BioNTech and Shanghai Henlius Biotech are actively involved.

CD137 antibodies, particularly agonistic antibodies, are the most advanced in development. These antibodies aim to activate CD137 signaling, boosting T-cell activity. Early clinical results have shown promising anti-tumor effects.

However, challenges such as hepatotoxicity have emerged. Therefore, alternative strategies like bispecific antibodies and tailored ligands are being explored for improved safety and efficacy.

Combining CD137-targeted therapies with other immunomodulators holds great promise. Preclinical and early clinical studies have demonstrated synergistic effects when paired with checkpoint inhibitors or other therapies. This approach enhances anti-tumor responses, addressing the unmet need for effective treatments.

The potential market for CD137 antibodies is substantial, given their broad applications in cancer. The development of these therapies is expected to improve outcomes and expand treatment options for various cancer types.

Source link: http://www.businesswire.com/news/home/20240918752552/en/CD137-Antibodies-Clinical-Trials-Market-Opportunity-Insight-2027—Over-80-Drugs-In-Clinical-Trials—ResearchAndMarkets.com

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.